<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29599784</article-id>
<article-id pub-id-type="pmc">5863269</article-id>
<article-id pub-id-type="doi">10.3389/fimmu.2018.00543</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Disease Evolution and Response to Rapamycin in Activated Phosphoinositide
3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated
Phosphoinositide 3-Kinase δ Syndrome Registry</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Maccari</surname>
<given-names>Maria Elena</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
<uri xlink:href="https://frontiersin.org/people/u/499477" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abolhassani</surname>
<given-names>Hassan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/84994" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aghamohammadi</surname>
<given-names>Asghar</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/419721" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aiuti</surname>
<given-names>Alessandro</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aleinikova</surname>
<given-names>Olga</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/512839" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bangs</surname>
<given-names>Catherine</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baris</surname>
<given-names>Safa</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/512118" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barzaghi</surname>
<given-names>Federica</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baxendale</surname>
<given-names>Helen</given-names>
</name>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/363785" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buckland</surname>
<given-names>Matthew</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/512817" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burns</surname>
<given-names>Siobhan O.</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/257764" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cancrini</surname>
<given-names>Caterina</given-names>
</name>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/453401" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cant</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="aff13">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cathébras</surname>
<given-names>Pascal</given-names>
</name>
<xref ref-type="aff" rid="aff14">
<sup>14</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cavazzana</surname>
<given-names>Marina</given-names>
</name>
<xref ref-type="aff" rid="aff15">
<sup>15</sup>
</xref>
<xref ref-type="aff" rid="aff16">
<sup>16</sup>
</xref>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chandra</surname>
<given-names>Anita</given-names>
</name>
<xref ref-type="aff" rid="aff18">
<sup>18</sup>
</xref>
<xref ref-type="aff" rid="aff19">
<sup>19</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conti</surname>
<given-names>Francesca</given-names>
</name>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/512516" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Coulter</surname>
<given-names>Tanya</given-names>
</name>
<xref ref-type="aff" rid="aff20">
<sup>20</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/512722" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Devlin</surname>
<given-names>Lisa A.</given-names>
</name>
<xref ref-type="aff" rid="aff20">
<sup>20</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Edgar</surname>
<given-names>J. David M.</given-names>
</name>
<xref ref-type="aff" rid="aff20">
<sup>20</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faust</surname>
<given-names>Saul</given-names>
</name>
<xref ref-type="aff" rid="aff21">
<sup>21</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fischer</surname>
<given-names>Alain</given-names>
</name>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
<xref ref-type="aff" rid="aff22">
<sup>22</sup>
</xref>
<xref ref-type="aff" rid="aff23">
<sup>23</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garcia-Prat</surname>
<given-names>Marina</given-names>
</name>
<xref ref-type="aff" rid="aff24">
<sup>24</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/522368" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hammarström</surname>
<given-names>Lennart</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/415223" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Heeg</surname>
<given-names>Maximilian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jolles</surname>
<given-names>Stephen</given-names>
</name>
<xref ref-type="aff" rid="aff25">
<sup>25</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/385158" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karakoc-Aydiner</surname>
<given-names>Elif</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kindle</surname>
<given-names>Gerhard</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kiykim</surname>
<given-names>Ayca</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/512138" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumararatne</surname>
<given-names>Dinakantha</given-names>
</name>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grimbacher</surname>
<given-names>Bodo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/231651" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Longhurst</surname>
<given-names>Hilary</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mahlaoui</surname>
<given-names>Nizar</given-names>
</name>
<xref ref-type="aff" rid="aff22">
<sup>22</sup>
</xref>
<xref ref-type="aff" rid="aff26">
<sup>26</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/257931" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Milota</surname>
<given-names>Tomas</given-names>
</name>
<xref ref-type="aff" rid="aff27">
<sup>27</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/534639" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moreira</surname>
<given-names>Fernando</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moshous</surname>
<given-names>Despina</given-names>
</name>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
<xref ref-type="aff" rid="aff22">
<sup>22</sup>
</xref>
<xref ref-type="aff" rid="aff23">
<sup>23</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mukhina</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="aff28">
<sup>28</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Neth</surname>
<given-names>Olaf</given-names>
</name>
<xref ref-type="aff" rid="aff29">
<sup>29</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Neven</surname>
<given-names>Benedicte</given-names>
</name>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
<xref ref-type="aff" rid="aff22">
<sup>22</sup>
</xref>
<xref ref-type="aff" rid="aff30">
<sup>30</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nieters</surname>
<given-names>Alexandra</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olbrich</surname>
<given-names>Peter</given-names>
</name>
<xref ref-type="aff" rid="aff29">
<sup>29</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/394894" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ozen</surname>
<given-names>Ahmet</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pachlopnik Schmid</surname>
<given-names>Jana</given-names>
</name>
<xref ref-type="aff" rid="aff31">
<sup>31</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Picard</surname>
<given-names>Capucine</given-names>
</name>
<xref ref-type="aff" rid="aff32">
<sup>32</sup>
</xref>
<xref ref-type="aff" rid="aff33">
<sup>33</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prader</surname>
<given-names>Seraina</given-names>
</name>
<xref ref-type="aff" rid="aff31">
<sup>31</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rae</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="aff21">
<sup>21</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reichenbach</surname>
<given-names>Janine</given-names>
</name>
<xref ref-type="aff" rid="aff31">
<sup>31</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/25354" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rusch</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Savic</surname>
<given-names>Sinisa</given-names>
</name>
<xref ref-type="aff" rid="aff32">
<sup>32</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/405503" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scarselli</surname>
<given-names>Alessia</given-names>
</name>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/424193" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scheible</surname>
<given-names>Raphael</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sediva</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="aff27">
<sup>27</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharapova</surname>
<given-names>Svetlana O.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/98486" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shcherbina</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="aff28">
<sup>28</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/431819" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Slatter</surname>
<given-names>Mary</given-names>
</name>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soler-Palacin</surname>
<given-names>Pere</given-names>
</name>
<xref ref-type="aff" rid="aff24">
<sup>24</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stanislas</surname>
<given-names>Aurelie</given-names>
</name>
<xref ref-type="aff" rid="aff15">
<sup>15</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suarez</surname>
<given-names>Felipe</given-names>
</name>
<xref ref-type="aff" rid="aff23">
<sup>23</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tucci</surname>
<given-names>Francesca</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uhlmann</surname>
<given-names>Annette</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/534700" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Montfrans</surname>
<given-names>Joris</given-names>
</name>
<xref ref-type="aff" rid="aff34">
<sup>34</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Warnatz</surname>
<given-names>Klaus</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/19333" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Anthony Peter</given-names>
</name>
<xref ref-type="aff" rid="aff21">
<sup>21</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wood</surname>
<given-names>Phil</given-names>
</name>
<xref ref-type="aff" rid="aff35">
<sup>35</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kracker</surname>
<given-names>Sven</given-names>
</name>
<xref ref-type="aff" rid="aff16">
<sup>16</sup>
</xref>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/508158" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Condliffe</surname>
<given-names>Alison Mary</given-names>
</name>
<xref ref-type="aff" rid="aff36">
<sup>36</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/502087" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ehl</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/121687" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Center for Chronic Immunodeficiency, Medical Center
– University of Freiburg</institution>, <addr-line>Freiburg</addr-line>,
<country>Germany</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Pediatrics and Adolescent Medicine,
Medical Center – University of Freiburg</institution>,
<addr-line>Freiburg</addr-line>, <country>Germany</country></aff>
<aff id="aff3"><sup>3</sup><institution>Division of Clinical Immunology, Department of
Laboratory Medicine, Karolinska Institute at Karolinska University Hospital
Huddinge</institution>, <addr-line>Stockholm</addr-line>,
<country>Sweden</country></aff>
<aff id="aff4"><sup>4</sup><institution>Research Center for Immunodeficiencies, Pediatric
Center of Excellence, Children’s Medical Center, Tehran University of Medical
Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff>
<aff id="aff5"><sup>5</sup><institution>San Raffaele Telethon Institute for Gene Therapy
(SR-TIGET), Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS
San Raffaele Scientific Institute</institution>, <addr-line>Milan</addr-line>,
<country>Italy</country></aff>
<aff id="aff6"><sup>6</sup><institution>Research Department, Belarusian Research Center for
Pediatric Oncology, Hematology and Immunology</institution>,
<addr-line>Minsk</addr-line>, <country>Belarus</country></aff>
<aff id="aff7"><sup>7</sup><institution>Central Manchester University Hospitals NHS
Foundation Trust</institution>, <addr-line>Manchester</addr-line>, <country>United
Kingdom</country></aff>
<aff id="aff8"><sup>8</sup><institution>Division of Pediatric Allergy/Immunology, Marmara
University</institution>, <addr-line>Istanbul</addr-line>,
<country>Turkey</country></aff>
<aff id="aff9"><sup>9</sup><institution>Cambridge Centre for Lung Defense, Papworth
Hospital</institution>, <addr-line>Cambridge</addr-line>, <country>United
Kingdom</country></aff>
<aff id="aff10"><sup>10</sup><institution>Institute of Immunity and Transplantation, Royal
Free Hospital</institution>, <addr-line>London</addr-line>, <country>United
Kingdom</country></aff>
<aff id="aff11"><sup>11</sup><institution>University Department of Pediatrics, Bambino
Gesù Children’s Hospital IRCCS</institution>,
<addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff12"><sup>12</sup><institution>Department of Systems Medicine, University of
Rome Tor Vergata</institution>, <addr-line>Rome</addr-line>,
<country>Italy</country></aff>
<aff id="aff13"><sup>13</sup><institution>Department of Paediatric Immunology, Newcastle
upon Tyne Hospital NHS Foundation Trust</institution>, <addr-line>Newcastle upon
Tyne</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff14"><sup>14</sup><institution>Internal Medicine, University Hospital of
Saint-Etienne</institution>, <addr-line>Saint-Etienne</addr-line>,
<country>France</country></aff>
<aff id="aff15"><sup>15</sup><institution>Biotherapy Department, Assistance
Publique-Hôpitaux de Paris (AP-HP), Necker Children’s
Hospital</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff16"><sup>16</sup><institution>Laboratory of Human Lymphohematopoiesis, INSERM
UMR 1163, Imagine Institute</institution>, <addr-line>Paris</addr-line>,
<country>France</country></aff>
<aff id="aff17"><sup>17</sup><institution>Paris Descartes-Sorbonne Paris Cité
University</institution>, <addr-line>Paris</addr-line>,
<country>France</country></aff>
<aff id="aff18"><sup>18</sup><institution>Department of Clinical Immunology, Addenbrookes
Hospital</institution>, <addr-line>Cambridge</addr-line>, <country>United
Kingdom</country></aff>
<aff id="aff19"><sup>19</sup><institution>Department of Medicine, University of
Cambridge</institution>, <addr-line>Cambridge</addr-line>, <country>United
Kingdom</country></aff>
<aff id="aff20"><sup>20</sup><institution>Regional Immunology Service, The Royal Hospitals
&amp; Queen’s University</institution>, <addr-line>Belfast</addr-line>,
<country>United Kingdom</country></aff>
<aff id="aff21"><sup>21</sup><institution>NIHR Clinical Research Facility, University
Hospital Southampton NHSFT</institution>, <addr-line>Southampton</addr-line>,
<country>United Kingdom</country></aff>
<aff id="aff22"><sup>22</sup><institution>Department of Pediatric Immunology, Hematology
and Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker
Children’s Hospital</institution>, <addr-line>Paris</addr-line>,
<country>France</country></aff>
<aff id="aff23"><sup>23</sup><institution>INSERM UMR 1163, Imagine Institute</institution>,
<addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff24"><sup>24</sup><institution>Pediatric Infectious Diseases and
Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall
d’Hebron Research Institute (VHIR)</institution>,
<addr-line>Barcelona</addr-line>, <country>Spain</country></aff>
<aff id="aff25"><sup>25</sup><institution>Immunodeficiency Centre for Wales, University
Hospital of Wales</institution>, <addr-line>Cardiff</addr-line>, <country>United
Kingdom</country></aff>
<aff id="aff26"><sup>26</sup><institution>French National Reference Center for Primary
Immune Deficiencies (CEREDIH), Necker Enfants Malades University Hospital, Assistance
Publique-Hôpitaux de Paris</institution>, <addr-line>Paris</addr-line>,
<country>France</country></aff>
<aff id="aff27"><sup>27</sup><institution>Department of Immunology, 2nd Faculty of Medicine
Charles University and Motol University Hospital</institution>,
<addr-line>Prague</addr-line>, <country>Czechia</country></aff>
<aff id="aff28"><sup>28</sup><institution>Department of Immunology, Research and Clinical
Center for Pediatric Hematology, Oncology and Immunology</institution>,
<addr-line>Moscow</addr-line>, <country>Russia</country></aff>
<aff id="aff29"><sup>29</sup><institution>Sección de Infectologıa,
Rheumatología and Inmunodeficiencias, Unidad de Pediatria, Hospital Virgen
del Rocıo, Instituto de Biomedicina de Sevilla (IBiS)</institution>,
<addr-line>Sevilla</addr-line>, <country>Spain</country></aff>
<aff id="aff30"><sup>30</sup><institution>Laboratory of Immunogenetics of Pediatric
Autoimmunity, INSERM UMR 1163, Imagine Institute</institution>,
<addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff31"><sup>31</sup><institution>Division of Immunology, University
Children’s Hospital Zurich and Children’s Research Centre, University
Zurich</institution>, <addr-line>Zurich</addr-line>,
<country>Switzerland</country></aff>
<aff id="aff32"><sup>32</sup><institution>Study Center for Primary Immunodeficiencies,
Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris
(AP-HP), Necker Medical School</institution>, <addr-line>Paris</addr-line>,
<country>France</country></aff>
<aff id="aff33"><sup>33</sup><institution>Laboratory of Lymphocyte Activation and
Susceptibility to EBV Infection, INSERM UMR 1163, Imagine Institute</institution>,
<addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff34"><sup>34</sup><institution>Wilhelmina Children’s
Hospital</institution>, <addr-line>Utrecht</addr-line>,
<country>Netherlands</country></aff>
<aff id="aff35"><sup>35</sup><institution>Department of Clinical Immunology and Allergy, St
James’s University Hospital</institution>, <addr-line>Leeds</addr-line>,
<country>United Kingdom</country></aff>
<aff id="aff36"><sup>36</sup><institution>Department of Infection, Immunity and
Cardiovascular Science, University of Sheffield</institution>,
<addr-line>Sheffield</addr-line>, <country>United Kingdom</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Stuart G. Tangye, Garvan Institute of Medical Research, Australia</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Shigeaki Nonoyama, National Defense Medical College, Japan; Kahn
Preece, The University of Queensland, Australia</p>
</fn>
<corresp content-type="corresp" id="cor1">*Correspondence: Maria Elena Maccari,
<email>maria.elena.maccari@uniklinik-freiburg.de</email></corresp>
<fn fn-type="other" id="fn001">
<p><sup>†</sup>These authors have contributed equally to the work.</p>
</fn>
<fn fn-type="other" id="fn002">
<p>Specialty section: This article was submitted to Primary Immunodeficiencies, a
section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>543</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>12</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Maccari, Abolhassani, Aghamohammadi,
Aiuti, Aleinikova, Bangs, Baris, Barzaghi, Baxendale, Buckland, Burns, Cancrini,
Cant, Cathébras, Cavazzana, Chandra, Conti, Coulter, Devlin, Edgar, Faust,
Fischer, Prat, Hammarström, Heeg, Jolles, Karakoc-Aydiner, Kindle, Kiykim,
Kumararatne, Grimbacher, Longhurst, Mahlaoui, Milota, Moreira, Moshous, Mukhina,
Neth, Neven, Nieters, Olbrich, Ozen, Schmid, Picard, Prader, Rae, Reichenbach, Rusch,
Savic, Scarselli, Scheible, Sediva, Sharapova, Shcherbina, Slatter, Soler-Palacin,
Stanislas, Suarez, Tucci, Uhlmann, van Montfrans, Warnatz, Williams, Wood, Kracker,
Condliffe and Ehl.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Maccari, Abolhassani, Aghamohammadi, Aiuti, Aleinikova, Bangs, Baris,
Barzaghi, Baxendale, Buckland, Burns, Cancrini, Cant, Cathébras, Cavazzana,
Chandra, Conti, Coulter, Devlin, Edgar, Faust, Fischer, Prat, Hammarström,
Heeg, Jolles, Karakoc-Aydiner, Kindle, Kiykim, Kumararatne, Grimbacher, Longhurst,
Mahlaoui, Milota, Moreira, Moshous, Mukhina, Neth, Neven, Nieters, Olbrich, Ozen,
Schmid, Picard, Prader, Rae, Reichenbach, Rusch, Savic, Scarselli, Scheible, Sediva,
Sharapova, Shcherbina, Slatter, Soler-Palacin, Stanislas, Suarez, Tucci, Uhlmann, van
Montfrans, Warnatz, Williams, Wood, Kracker, Condliffe and Ehl</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner are credited
and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by
autosomal dominant mutations in <italic>PIK3CD</italic> (APDS1) or
<italic>PIK3R1</italic> (APDS2), is a heterogeneous primary immunodeficiency.
While initial cohort-descriptions summarized the spectrum of clinical and
immunological manifestations, questions about long-term disease evolution and
response to therapy remain. The prospective European Society for Immunodeficiencies
(ESID)-APDS registry aims to characterize the disease course, identify outcome
predictors, and evaluate treatment responses. So far, 77 patients have been recruited
(51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients
pinpoints the early occurrence of recurrent respiratory infections followed by
chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias.
Although most manifestations occur by age 15, adult-onset and asymptomatic courses
were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a
CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had
received at least one immunosuppressant, but 2–3 lines of immunosuppressive
therapy were not unusual before age 10. Response to rapamycin was rated by physician
visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation
showed the best response (8 complete, 11 partial, 6 no remission), while bowel
inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2
partial, 9 no remission) responded less well. Hence, non-lymphoproliferative
manifestations should be a key target for novel therapies. This report from the
ESID-APDS registry provides comprehensive baseline documentation for a growing cohort
that will be followed prospectively to establish prognostic factors and identify
patients for treatment studies.</p>
</abstract>
<kwd-group>
<kwd>activated phosphoinositide 3-kinase δ syndrome</kwd>
<kwd>PIK3CD</kwd>
<kwd>PIK3R1</kwd>
<kwd>registry</kwd>
<kwd>natural history</kwd>
<kwd>rapamycin</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn01">GlaxoSmithKline<named-content content-type="fundref-id">10.13039/100004330</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn02">Novartis<named-content content-type="fundref-id">10.13039/100004336</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn03">UCB UK<named-content content-type="fundref-id">10.13039/100011111</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn04">Bundesministerium für Bildung und
Forschung<named-content content-type="fundref-id">10.13039/501100002347</named-content></funding-source>
<award-id rid="cn04">BMBF 01E01303</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="15"></ref-count>
<page-count count="8"></page-count>
<word-count count="5335"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>Heterozygous gain-of-phosphoinositide 3-kinase (PI3K) δ-function mutations in
<italic>PIK3CD</italic> or <italic>PIK3R1</italic> cause an autosomal-dominant
primary immunodeficiency (PID) called activated phosphoinositide 3-kinase δ
syndrome (APDS) or PASLI (p110-delta-activating mutation causing senescent T cells,
lymphadenopathy, and immunodeficiency) 1 and 2, respectively (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B4">4</xref>). The main clinical
and immunological characteristics of APDS 1 and 2 have been recently described in two
major retrospective cohort studies (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Recurrent respiratory infections and benign
lymphoproliferation emerged as key clinical aspects of the disease in both cohorts.
Bronchiectasis was noted as a frequent complication with 60% in the APDS1 cohort and
less frequently (18%) in the APDS2 cohort study. Additional immune dysregulation
including cytopenias, glomerulonephritis, arthritis, and colitis was reported in these
studies. An increased risk for lymphoma was also highlighted with 13% among the APDS1
patients and 28% in the APDS2 cohort. Non-immunological characteristics included
neurodevelopmental delay (19% of APDS1 and 31% of APDS2) and growth impairment,
especially among APDS2 patients (45%). Immunologically, hypogammaglobulinemia with
increased IgM levels was frequent. B-cell lymphopenia, worsening with age, and expansion
of transitional B cells were the main B-cell alterations. A reduction in the frequency
of naïve CD4<sup>+</sup> and CD8<sup>+</sup> T cells with an
increased frequency of effector/effector memory CD8<sup>+</sup> T cells was
reported. These first two important retrospective analyses of the disease illustrated
clinical and immunological characteristics but did not address the dynamics of the
disease evolution over time. Furthermore, although both reports showed that the majority
of APDS patients receive supportive therapies in terms of immunoglobulin-replacement
treatment (IGRT) or antimicrobial prophylaxes, data regarding immunosuppressive
treatments were only reported for a limited number of patients. Here, we use an initial
report from the European Society for Immunodeficiencies (ESID)-APDS prospective registry
to address some of these questions.</p>
</sec>
<sec id="S2" sec-type="methods">
<title>Methods</title>
<sec id="S2-1">
<title>The ESID-APDS Registry: Goals and Design</title>
<p>The ESID is a not-for-profit association whose aim is to improve knowledge in the
field of PIDs (<uri xlink:href="https://www.esid.org" xlink:type="simple">www.esid.org</uri>). The ESID
Registry is an international Internet-based database for basic epidemiological (level
1), and more extensive disease-specific (level 3) data on patients with PID. The APDS
Registry is the first prospective level 3 project that was initiated to better define
the natural history of patients with APDS. The study is carried out in accordance
with the recommendations of Section 15 of the Code of Conduct of the General Medical
Council of Baden-Württemberg, Germany. The protocol was approved by the
Ethics committee of the University of Freiburg (IRB approval No. ESID registry:
493/14; IRB approval No. APDS registry: 458/15). All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The goals of the project are
to characterize disease evolution over time, to establish prognostic factors and
biomarkers, to assess the impact of various treatment strategies, and to identify
patients who could be eligible for novel treatments and interventions. Entry into the
database requires an initial retrospective documentation, followed by yearly
prospective follow-ups. Because of required patient consent, deceased patients cannot
be registered. Each patient is evaluated at entry for eligibility by one of the three
chief investigators to ensure that only patients with functionally validated
APDS-associated mutations are registered. The APDS registry is supported by the
pharmaceutical companies Novartis, GlaxoSmithKline, and UCB UK, who financed
development and maintenance of the online level 3-documentation-section for APDS as
well as project management including ethics submission in all participating
countries, data management, and quality controls.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3-1">
<title>Disease Manifestations and Their Evolution Over Time</title>
<p>By December 2017, 77 patients had been enrolled in the APDS Registry, 51 with APDS1,
and 26 with APDS2. Detailed clinical and immunological information of 68 patients [39
of them not published in the cohort papers (<xref ref-type="bibr" rid="B5">5</xref>,
<xref ref-type="bibr" rid="B6">6</xref>)] from 59 unrelated families was available
for this initial analysis. Forty-five of these 68 patients were diagnosed with APDS1
(43 with the E1021K and 2 with the C416R mutation) and 23 with APDS2 (all with
mutations leading to skipping of exon 11). At the time of evaluation, living patients
(65) had a mean age of 17.9 years (range 3–47 years). The
main clinical features reported in APDS1 and APDS2 are summarized in Figures <xref ref-type="fig" rid="F1">1</xref>A,B. As in the previously reported cohorts,
recurrent respiratory infections were by far the most frequent manifestation,
occurring in 96% of the patients. Upper respiratory tract infections, otitis media,
and sinusitis were the leading diagnoses, and, importantly, 59% of the patients had
experienced at least one episode of pneumonia. Cumulative retrospective data
highlight that the respiratory infections begin very early in life, with almost all
patients being affected by the age of 15 (Figure <xref ref-type="fig" rid="F1">1</xref>C). The registry data confirmed the previously described (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>) high
incidence of bronchiectasis (28 patients out of the 55 who underwent a CT-scan),
which was documented early in life (age range: 2–39 years; mean:
11.2 years). As already suggested by a previous retrospective review of the
literature (<xref ref-type="bibr" rid="B7">7</xref>), the majority of patients with
bronchiectasis had APDS1 (24 patients out of the 40 who had a CT-scan). Abnormal lung
function was noted in 17 out of 35 patients who performed these tests. Acute viral
infections (with varicella and herpes simplex) as well as chronic viral
infections/reactivations were frequently documented in APDS1 and APDS2 patients
(Figure <xref ref-type="fig" rid="F1">1</xref>A). The most frequently reported
chronic infection in both cohorts was Epstein–Barr virus infection (16/68).
Among the non-respiratory bacterial infections, the most frequent was infectious
lymphadenitis (14/68). Five patients suffered from chronic mucocutaneous candidiasis
and three developed local infection following vaccination with bacillus
Calmette–Guérin. Consistent with the two published cohorts, chronic
non-neoplastic lymphoproliferation was reported in the majority of patients (87%).
Persistent peripheral lymphoproliferation, splenomegaly, and lymphoid hyperplasia
were frequent and they were often concomitantly reported in the same patients (Figure
<xref ref-type="fig" rid="F1">1</xref>D). Across the cohort, lymphoproliferation
occurred with later onset than respiratory infections (Figure <xref ref-type="fig" rid="F1">1</xref>C) but preceded gastrointestinal manifestations and the
development of autoimmunity.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>(A)</bold> Incidence of infections in APDS1 and APDS2 patients.
<bold>(B)</bold> Incidence of manifestations of immune dysregulation in
APDS1 and APDS2 patients. <bold>(C)</bold> Evolution of disease
manifestations over time. Information regarding age at onset available for:
respiratory infections <italic>n</italic> = 62/65,
lymphoproliferation <italic>n</italic> = 59/59,
gastrointestinal manifestations
<italic>n</italic> = 33/35, cytopenia
<italic>n</italic> = 20/21 patients.
<bold>(D)</bold> Diagram showing the different types of benign
lymphoproliferative manifestations. <bold>(E)</bold> Diagram showing
the different blood lineages affected in patients with cytopenias.</p>
</caption>
<graphic xlink:href="fimmu-09-00543-g001"></graphic>
</fig>
<p>Benign lymphoproliferation may be difficult to distinguish from malignant disease,
the risk of which is increased in APDS patients. Eight of the registry-documented
patients (5 APDS1, 3 APDS2) developed lymphoma between the age of 11 and
25 years, including two patients with Hodgkin lymphoma, one of whom
subsequently developed an intestinal diffuse large B-cell lymphoma. Six patients were
diagnosed with non-Hodgkin lymphomas (two diffuse large B-cell lymphomas, one
anaplastic lymphoma, one marginal zone lymphoma, two without detailed histologic
information). Five patients achieved a complete remission on treatment, one patient
achieved only a partial remission, one patient was still under treatment at the time
of registration, while in the remaining case, the lymphoma was sadly fatal. One of
these eight patients also had a benign ovarian serous cystadenoma. One patient
developed a B-cell chronic lymphocytic leukemia at the age of 40 years. In
addition to the established high incidence of hematological malignancy, 2 cases of
solid organ malignancy or pre-malignancy were noted: one case of ductal breast
carcinoma-<italic>in situ</italic> (diagnosed in an APDS2 patient at the age of
33) and one case of rhabdomyosarcoma (diagnosed in an APDS1 patient at the age of
13).</p>
<p>Gastrointestinal manifestations were the third most frequent disease manifestation
(51%) and across the cohort occurred before the other features of immune
dysregulation, such as cytopenias or arthritis, but typically much later than the
respiratory infections and the benign lymphoproliferation (Figures <xref ref-type="fig" rid="F1">1</xref>B,C). Small or large bowel inflammation was
histologically confirmed in 17 patients, in 11 of them by the age of
10 years. Granulomas were reported in only one patient. Protracted diarrhea
with no identified underlying cause was the second commonest reported
gastrointestinal problem and was often severe enough to require hospitalization. Two
patients were diagnosed with autoimmune hepatitis but no cases of sclerosing
cholangitis were reported, in contrast with the two patients reported by Coulter et
al. (<xref ref-type="bibr" rid="B5">5</xref>) and the two reported by Hartman et al.
(<xref ref-type="bibr" rid="B8">8</xref>). Of note, 14/68 patients of the
APDS-Registry cohort had eczema. Elkaim et al. (<xref ref-type="bibr" rid="B6">6</xref>) noted only three APDS2 patients with chronic eczema and no inflammatory
skin disease was mentioned in the published APDS1 cohort (<xref ref-type="bibr" rid="B5">5</xref>). Cytopenias were the fourth major disease manifestation
affecting around 30% of patients, usually later in life (Figures <xref ref-type="fig" rid="F1">1</xref>B,C) than the other main features and frequently affecting
multiple blood lines (Figure <xref ref-type="fig" rid="F1">1</xref>E). The autoimmune
origin of the cytopenias could be documented in the majority of the patients. Other
autoimmune diseases were also reported, all occurring after the age of
10 years: two patients had autoimmune thyroiditis, three had arthritis, and
three glomerulonephritis.</p>
<p>Concerning non-immunological manifestations, short stature (&gt;2 SD) was
reported in 11 patients, with a predominance of APDS2 individuals (8/13), consistent
with previous reports (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Neurodevelopmental delay was diagnosed in three patients.
Specific neuropsychiatric disorders were also reported: one patient had Asperger
Syndrome, one had autism, one suffered from a mixed anxiety and depression disorder,
and two other patients had mild disorders of speech and language development. It is
unclear if these findings reflect the impact of a severe physical illness or the
impact of enhanced PI3Kδ signaling in the central nervous system.</p>
</sec>
<sec id="S3-2">
<title>Immunological Abnormalities</title>
<p>One of the objectives of the ESID-APDS registry is to collect immunological data
prospectively. An initial analysis of the immunological profile in the registry
cohort confirmed the already published T- and B-cell alterations. No clear difference
between APDS1 and 2 was detected in the current cross-sectional data set. In the
future, the longitudinal collection and analysis of these data will offer the
possibility to explore associations between specific disease manifestations and
immunological alterations, to evaluate the response of immunological alterations to
the different types of treatment, and to establish the predictive value of
immunological parameters for disease prognosis.</p>
</sec>
<sec id="S3-3">
<title>Current Therapies</title>
<p>Supportive therapy is a key component of the management of APDS patients. In the
APDS-registry, 54 patients received antibiotic prophylaxis, whereas only eight
received antifungal prophylaxis, which appears justified given the absence of
reported invasive fungal infections. IGRT was administered in 44 patients (28/45
APDS1, 16/23 APDS2), was in general very well tolerated, and was started early in
life (Figure <xref ref-type="fig" rid="F2">2</xref>A), mirroring the early
presentation with respiratory infections. The majority of patients also received
immunosuppressive treatments. Thirty-one patients received corticosteroids and 27 of
them showed at least a partial clinical benefit. More than half had received steroid
treatment by the age of 20 (Figure <xref ref-type="fig" rid="F2">2</xref>A).
Thirty-six patients received other immunosuppressive drugs, including azathioprine
(<italic>n</italic> = 1), mycophenolate
(<italic>n</italic> = 3), cyclosporine
(<italic>n</italic> = 5), or rapamycin
(<italic>n</italic> = 27); clinical benefit was reported in
28 of these patients. Rituximab was given to eight patients, with clinical benefit in
all. Figure <xref ref-type="fig" rid="F2">2</xref>B illustrates the multiple lines of
immunosuppressive treatments (steroids, immunosuppressive drugs, or rituximab), which
had already been received by patients by the time of enrollment into the registry.
Five patients underwent splenectomy (4 APDS1 and 1 APDS2) because of cytopenias or
splenomegaly and 25 patients (12 APDS1 and 13 APDS2) underwent tonsillectomy (age
range: 1–12 years), with clear benefit in only seven of them. The
only available curative option is hematopoietic stem cell transplantation (HSCT) and
the first experiences in this field have been published (<xref ref-type="bibr" rid="B9">9</xref>). Among the patients in the registry, 8/68 patients had
undergone HSCT (7 APDS1 and 1 APDS2) by the time of registration (Figure <xref ref-type="fig" rid="F2">2</xref>A), with fatal outcome in one.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>(A)</bold> Use of treatment modalities over time. IGRT,
immunoglobulin-replacement-treatment; IS, immunosuppressive drug; HSCT,
hematopoietic stem cell transplantation. Information regarding age at first
therapy available for: IGRT <italic>n</italic> = 28/44,
steroid therapy <italic>n</italic> = 31/31, IS therapy
<italic>n</italic> = 35/36,
HSCT = 8/8. <bold>(B)</bold> Number of lines of
immunosuppressive treatments (steroids, immunosuppressive drugs, rituximab) by
the time of registration; red: patients who had undergone HSCT by the time of
registration. <bold>(C)</bold> Response to rapamycin treatment.
<italic>White</italic>: complete response; <italic>gray</italic>: partial
response; <italic>black</italic>: no response; <italic>red</italic>: worsened
or new manifestation; <italic>boxes with a diagonal</italic>: manifestation not
present in this patient. CR, complete remission; PR, partial remission.
Rapamycin stopped because of: *non-compliance, °inefficiency,
<sup>^</sup>side effects, <sup>§</sup>clinical trial.
<bold>(D)</bold> Overall clinical benefit (Visual Analog Scale) according to
physician’s evaluation.</p>
</caption>
<graphic xlink:href="fimmu-09-00543-g002"></graphic>
</fig>
</sec>
<sec id="S3-4">
<title>Rapamycin Therapy in APDS</title>
<p>Consistent with activation of mTOR signaling downstream of the activated
PI3Kδ, patients with APDS may benefit from rapamycin (<xref ref-type="bibr" rid="B2">2</xref>). In the APDS2 cohort-paper (<xref ref-type="bibr" rid="B6">6</xref>), six patients had been treated with rapamycin, but the time of
follow-up was too short to evaluate the response to treatment in four of them. Six of
the patients in the reported APDS1 cohort (<xref ref-type="bibr" rid="B5">5</xref>)
were treated with rapamycin for benign lymphoproliferation; five of them had a
treatment response, but in one case, the therapy was stopped due to side effects.
Additional case reports of rapamycin therapy have also been published (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>). In
the ESID-APDS-registry cohort, rapamycin was the most frequently used
immunosuppressive drug. We, therefore, decided to evaluate the experience with
rapamycin (Sirolimus) in 26 patients (1 patient was not included because treatment
was started and terminated before the diagnosis of APDS and the response to therapy
was not well documented), 17 with APDS1, and 9 with APDS2. The main indications for
treatment were lymphoproliferation, colitis, and/or cytopenia. Physicians were asked
to judge the degree of severity of each manifestation as mild, moderate, or severe at
the start of therapy, following 3–6 months of treatment and at the
latest follow-up (average time of therapy monitoring: 1.6 years). Overall
response judged by the physician visual analog scale was good in 10, moderate in 9,
and poor in 7 (Figure <xref ref-type="fig" rid="F2">2</xref>D). Lymphoproliferation
showed the best response (8 complete, 11 partial, 6 no remission), while bowel
inflammation (3 complete, 3 partial, and 9 no remission) and cytopenia (3 complete, 2
partial, 9 no remission) responded less well, as shown in Figure <xref ref-type="fig" rid="F2">2</xref>C. Notably, of the eight patients who were on steroids at
initiation of treatment with rapamycin (No. 1, 7, 9, 13, 19, 22, 23, 25), seven were
able to stop steroids and one (No. 25) was able to reduce the dose. Two patients (No.
4, 5) stopped therapy because of poor compliance, in three cases (No. 6, 14, 15), the
reason for cessation was lack of efficacy. Two patients (No. 7, 13) suffered from
side effects (severe headaches, anorexia, renal toxicity) that led to the complete
interruption of the treatment, whereas in three cases, the therapy was paused because
of side effects (aphthous ulcers, liver toxicity, renal toxicity) but could be
started again. Two patients (No. 3, 8) stopped despite efficacy because of enrollment
in a clinical trial with PI3Kδ inhibitors. In two other individuals (No. 11,
12), treatment was interrupted after prolonged usage; in one patient (No. 20), this
was due to the patient planning for pregnancy and, in another (No. 19), it followed
the development of a lymphoma. Of note, three patients (No. 14, 18, 25) received also
Rituximab during and one (No. 10) shortly before the treatment with rapamycin. One
patient (No. 20) concomitantly received Adalimumab because of arthritis.
Interestingly, some patients did not show any relevant alterations in the disease
manifestations after 3–6 months of therapy but did show either
improvement (No. 1, 8, 10, 18, 22, 23) or worsening (No. 6, 14, 19) after a longer
period of observation on treatment (about 2 years).</p>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>We present an initial analysis of the prospective ESID-APDS registry, a longitudinal
cohort study of patients with APDS1 and APDS2. This overview expands the known
information regarding the clinical manifestations of the disease by adding the aspect of
the evolution of the features over time. The emerging picture is the one of a PID
characterized by the early occurrence of respiratory infections (mostly upper
respiratory infections), followed by the development of chronic benign
lymphoproliferation and subsequently other features of immune dysregulation, in
particular, gastrointestinal manifestations and autoimmune cytopenias. We again noted
the higher incidence of bronchiectasis in APDS1 compared with APDS2 patients; however,
the numbers remain small and differences in CT uptake cannot be excluded as a
confounder. However, this observation may stimulate future studies of the roles of the
<italic>PIK3CD</italic> and <italic>PIK3R1</italic> genes and their proteins in the
respiratory system. In the future, further analysis of the clinical evolution in this
prospective cohort will allow better definition of long-term prognosis for this disease.
In addition, the correlation of clinical features with the immunological abnormalities
and their relationship with outcome parameters will help defining clinical and
biological biomarkers of outcome.</p>
<p>The choice of treatment is a key issue in these patients who often present with severe
concomitant manifestations not only of immunodeficiency but also of immune
dysregulation. According to the registry, the combination of supportive therapy to
prevent recurrent infections and the immunosuppressive treatment of immune dysregulation
is often initiated early in life, with many patients undergoing multiple treatments.
Rapamycin inhibits the biologically relevant downstream PI3K effector mTOR pathway, and
it has been widely used with good efficacy in other PIDs, in particular, autoimmune
lymphoproliferative syndrome (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Our interrogation of the ESID-APDS registry
aligns with previous reports (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>) in suggesting that rapamycin reduces the
severity of benign lymphoproliferative disease also in APDS. However, a less
satisfactory response was documented regarding the non-lymphoproliferative
manifestations, in particular, intestinal disease and cytopenias, which can be highly
detrimental for the patients’ quality of life. It is important to relate these
registry results to the first results of targeted therapy with the PI3Kδ
inhibitor leniolisib that have recently been published (<xref ref-type="bibr" rid="B13">13</xref>). In the first six patients, the drug showed an excellent control of the
lymphoproliferation (6/6 patients) and in part also improved the cytopenias at the end
of treatment (day 84). Three of the six patients normalized their thrombocytopenia, one
patient resolved his anemia, and three of four patients improved their lymphopenia,
while there was no correction of the neutropenia observed in two patients; however,
respiratory and gastrointestinal symptoms and outcomes were not reported in this study.
Furthermore, our registry analysis highlighted that also colitis and skin disease can
cause significant symptoms in these patients and should, therefore, be carefully
evaluated in future clinical studies on novel therapies, particularly given previous
reports of colitis associated with PI3K inhibitors (<xref ref-type="bibr" rid="B14">14</xref>). Longitudinal data capture on APDS patients in the ESID-APDS registry
will be critical to observe the long-term benefits and/or side effects of these
therapies, in particular, their effect on the incidence of lymphomas. It is noteworthy
that one patient developed lymphoma while taking rapamycin. Another key question, where
the registry will be helpful, is the question if and when to perform HSCT. The analysis
of this question will profit from the principles established in the P-CID study, a
prospective natural history study on profound combined immunodeficiency in which matched
pairs of transplanted and non-transplanted patients with similar disease burden and
immunological alterations are followed (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>Finally, an attractive goal for the registry is to involve patients and their families
directly in data acquisition. This could in the future allow collecting information
about the quality-of-life of APDS patients, thus ameliorating the evaluation of the
disease burden in all its complexity. In summary, thanks to the collaborative work of
the participating centers, the ESID-APDS registry will comprise a valuable resource for
physicians dealing with this disease and for shaping future research questions.</p>
</sec>
<sec id="S5">
<title>Ethics Statement</title>
<p>The study is carried out in accordance with the recommendations of Section 15 of the
Code of Conduct of the General Medical Council of Baden-Württemberg, Germany.
The protocol was approved by the Ethics committee of the University of Freiburg (IRB
approval No. ESID registry: 493/14; IRB approval No. APDS registry: 458/15). All
subjects gave written informed consent in accordance with the Declaration of
Helsinki.</p>
</sec>
<sec id="S6">
<title>Author Contributions</title>
<p>MM collected analyzed and interpreted data and wrote the manuscript. HA, AA, ALA, OA,
CB, SAB, FB, HB, MB, SOB, CC, ANDC, PC, MC, ANIC, FC, TC, LD, JE, SF, AF, MG, LH, MH,
SJ, EK, AK, DK, BG, HL, NM, TM, FM, DM, AM, ON, BN, PO, AO, JP, CP, SP, JR, SS, ALS,
ANS, SS, ASH, MS, PS, AUS, FS, WR, FT, JM, KW, AW, and PW repeatedly referred and
registered patients. AN, GK and AU coordinated the registry. SR and RS provided the
export data from the online-registry and gave informatic support. SK, ALC, and SE
interpreted the data and wrote the manuscript. All the authors edited the
manuscript.</p>
</sec>
<sec id="S7">
<title>Conflict of Interest Statement</title>
<p>The APDS registry is supported by the pharmaceutical companies Novartis,
GlaxoSmithKline, and UCB UK, who have financed development and maintenance of the online
level 3 documentation section for APDS as well as project management including ethics
submission in all participating countries, data management, and quality controls. The
financial support also allows some reimbursement of documentation activities for the
participating centers. For those patients who have specifically agreed to this in the
registry consent, anonymized data from the APDS Registry are available to industry
partners for their purposes (e.g., designing a drug trial or data submission for
regulatory approvals).</p>
</sec>
</body>
<back>
<ack>
<p>We highly appreciate the continuous support by our study nurse Henrike Ritterbusch. The
registration of German patients is supported by pid-net (<uri xlink:href="https://www.pid-net.org" xlink:type="simple">www.pid-net.org</uri>). We thank all the
patients and families for their participation and trust.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was supported by the German Federal Ministry of
Education and Research (BMBF 01E01303). The ESID-APDS registry is supported by the
pharmaceutical companies Novartis, GlaxoSmithKline, and UCB UK.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angulo</surname><given-names>I</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Garçon</surname><given-names>F</given-names></name><name><surname>Banham-Hall</surname><given-names>E</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Leahy</surname><given-names>TR</given-names></name><etal></etal></person-group>
<article-title>Phosphoinositide 3-kinase delta gene mutation predisposes to
respiratory infection and airway damage</article-title>. <source/>Science
(<year>2013</year>)
<volume>342</volume>(<issue>6160</issue>):<fpage>866</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1126/science.1243292</pub-id><pub-id pub-id-type="pmid">24136356</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Niemela</surname><given-names>JE</given-names></name><name><surname>Deenick</surname><given-names>EK</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><etal></etal></person-group>
<article-title>Dominant-activating germline mutations in the gene encoding the PI(3)K
catalytic subunit p110delta result in T cell senescence and human
immunodeficiency</article-title>. <source/>Nat Immunol (<year>2014</year>)
<volume>15</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2771</pub-id><pub-id pub-id-type="pmid">24165795</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deau</surname><given-names>MC</given-names></name><name><surname>Heurtier</surname><given-names>L</given-names></name><name><surname>Frange</surname><given-names>P</given-names></name><name><surname>Suarez</surname><given-names>F</given-names></name><name><surname>Bole-Feysot</surname><given-names>C</given-names></name><name><surname>Nitschke</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>A human immunodeficiency caused by mutations in the PIK3R1
gene</article-title>. <source/>J Clin Invest (<year>2014</year>)
<volume>124</volume>(<issue>9</issue>):<fpage>3923</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1172/JCI75746</pub-id><pub-id pub-id-type="pmid">25133428</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Venida</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>McElwee</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Heterozygous splice mutation in PIK3R1 causes human immunodeficiency
with lymphoproliferation due to dominant activation of PI3K</article-title>.
<source/>J Exp Med (<year>2014</year>)
<volume>211</volume>(<issue>13</issue>):<fpage>2537</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20141759</pub-id><pub-id pub-id-type="pmid">25488983</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>TI</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Bacon</surname><given-names>CM</given-names></name><name><surname>Babar</surname><given-names>J</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Screaton</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Clinical spectrum and features of activated phosphoinositide 3-kinase
delta syndrome: a large patient cohort study</article-title>. <source/>J Allergy
Clin Immunol (<year>2017</year>)
<volume>139</volume>(<issue>2</issue>):<fpage>597</fpage>–<lpage>606.e4</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.06.021</pub-id><pub-id pub-id-type="pmid">27555459</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkaim</surname><given-names>E</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Bruneau</surname><given-names>J</given-names></name><name><surname>Mitsui-Sekinaka</surname><given-names>K</given-names></name><name><surname>Stanislas</surname><given-names>A</given-names></name><name><surname>Heurtier</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Clinical and immunologic phenotype associated with activated
phosphoinositide 3-kinase delta syndrome 2: a cohort study</article-title>.
<source/>J Allergy Clin Immunol (<year>2016</year>)
<volume>138</volume>(<issue>1</issue>):<fpage>210</fpage>–<lpage>8.e9</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.03.022</pub-id><pub-id pub-id-type="pmid">27221134</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olbrich</surname><given-names>P</given-names></name><name><surname>Lorenz</surname><given-names>M</given-names></name><name><surname>Cura Daball</surname><given-names>P</given-names></name><name><surname>Lucena</surname><given-names>JM</given-names></name><name><surname>Rensing-Ehl</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Activated PI3Kdelta syndrome type 2: two patients, a novel mutation,
and review of the literature</article-title>. <source/>Pediatr Allergy
Immunol (<year>2016</year>)
<volume>27</volume>(<issue>6</issue>):<fpage>640</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1111/pai.12585</pub-id><pub-id pub-id-type="pmid">27116393</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>HN</given-names></name><name><surname>Niemela</surname><given-names>J</given-names></name><name><surname>Hintermeyer</surname><given-names>MK</given-names></name><name><surname>Garofalo</surname><given-names>M</given-names></name><name><surname>Stoddard</surname><given-names>J</given-names></name><name><surname>Verbsky</surname><given-names>JW</given-names></name><etal></etal></person-group>
<article-title>Gain of function mutations of PIK3CD as a cause of primary sclerosing
cholangitis</article-title>. <source/>J Clin Immunol (<year>2015</year>)
<volume>35</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-014-0109-1</pub-id><pub-id pub-id-type="pmid">25352054</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nademi</surname><given-names>Z</given-names></name><name><surname>Slatter</surname><given-names>MA</given-names></name><name><surname>Dvorak</surname><given-names>CC</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Suarez</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Hematopoietic stem cell transplant in patients with activated PI3K
delta syndrome</article-title>. <source/>J Allergy Clin Immunol
(<year>2017</year>)
<volume>139</volume>(<issue>3</issue>):<fpage>1046</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.09.040</pub-id><pub-id pub-id-type="pmid">27847301</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rae</surname><given-names>W</given-names></name><name><surname>Ramakrishnan</surname><given-names>KA</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Ashton-Key</surname><given-names>M</given-names></name><name><surname>Pengelly</surname><given-names>RJ</given-names></name><name><surname>Patel</surname><given-names>SV</given-names></name><etal></etal></person-group>
<article-title>Precision treatment with sirolimus in a case of activated
phosphoinositide 3-kinase delta syndrome</article-title>. <source/>Clin
Immunol (<year>2016</year>)
<volume>171</volume>:<fpage>38</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2016.07.017</pub-id><pub-id pub-id-type="pmid">27444043</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemann</surname><given-names>C</given-names></name><name><surname>Esquivel</surname><given-names>M</given-names></name><name><surname>Magerus-Chatinet</surname><given-names>A</given-names></name><name><surname>Lorenz</surname><given-names>MR</given-names></name><name><surname>Fuchs</surname><given-names>I</given-names></name><name><surname>Neveux</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Evolution of disease activity and biomarkers on and off rapamycin in
28 patients with autoimmune lymphoproliferative syndrome</article-title>.
<source/>Haematologica (<year>2017</year>)
<volume>102</volume>(<issue>2</issue>):<fpage>e52</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.3324/haematol.2016.153411</pub-id><pub-id pub-id-type="pmid">27789675</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teachey</surname><given-names>DT</given-names></name><name><surname>Greiner</surname><given-names>R</given-names></name><name><surname>Seif</surname><given-names>A</given-names></name><name><surname>Attiyeh</surname><given-names>E</given-names></name><name><surname>Bleesing</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Treatment with sirolimus results in complete responses in patients
with autoimmune lymphoproliferative syndrome</article-title>. <source/>Br J
Haematol (<year>2009</year>)
<volume>145</volume>(<issue>1</issue>):<fpage>101</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.07595.x</pub-id><pub-id pub-id-type="pmid">19208097</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>VK</given-names></name><name><surname>Webster</surname><given-names>S</given-names></name><name><surname>Dalm</surname><given-names>VASH</given-names></name><name><surname>Šedivá</surname><given-names>A</given-names></name><name><surname>van Hagen</surname><given-names>PM</given-names></name><name><surname>Holland</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Effective “activated PI3Kdelta syndrome”-targeted
therapy with the PI3Kdelta inhibitor leniolisib</article-title>.
<source/>Blood (<year>2017</year>)
<volume>130</volume>(<issue>21</issue>):<fpage>2307</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2017-08-801191</pub-id><pub-id pub-id-type="pmid">28972011</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwell</surname><given-names>IB</given-names></name><name><surname>Ip</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>JB</given-names></name></person-group>
<article-title>PI3K inhibitors: understanding toxicity mechanisms
and management</article-title>. <source/>Oncology (Williston Park)
(<year>2017</year>)
<volume>31</volume>(<issue>11</issue>):<fpage>821</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">29179250</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speckmann</surname><given-names>C</given-names></name><name><surname>Doerken</surname><given-names>S</given-names></name><name><surname>Aiuti</surname><given-names>A</given-names></name><name><surname>Albert</surname><given-names>MH</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Allende</surname><given-names>LM</given-names></name><etal></etal></person-group>
<article-title>A prospective study on the natural history of patients with profound
combined immunodeficiency: an interim analysis</article-title>. <source/>J Allergy
Clin Immunol (<year>2017</year>)
<volume>139</volume>(<issue>4</issue>):<fpage>1302</fpage>–<lpage>10.e4</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.07.040</pub-id><pub-id pub-id-type="pmid">27658761</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>